Worthington & Caron Law Firm to Support 3rd International Symposium on Lung-Sparing Therapies for Mesothelioma

Share Article

The Worthington &Caron Law Firm is proud to once again serve as a sponsor for this unique symposium which focuses on rational lung-sparing surgical and non-surgical therapies for treating pleural mesothelioma. The firm has donated $50,000 for this year’s symposium, matching its contributions of the same amount for the first two years’ symposia.

3rd International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma

According to Dr. Cameron, "It is best for the patient to treat mesothelioma as a chronic illness while preserving the function of both lungs."

Mesothelioma experts will gather on Saturday, May 18, 2013 at the Sheraton Delfina Hotel in Santa Monica, California for the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma. Dr. Robert Cameron, Director of the UCLA Mesothelioma Comprehensive Research Program and Chief of Thoracic Surgery at the West Los Angeles VA Medical Center, will lead the symposium again this year. Dr. Cameron has been a leading innovator and proponent of lung-sparing treatments for mesothelioma for 20 years.

The distinguished faculty at this year’s meeting will include experts from Pittsburgh and Philadelphia, Pennsylvania, Bethesda, Maryland and as far away as Aviano, Italy, with additional experts in a wide range of medical and scientific fields. The seminar, which offers continuing medical education credit, is primarily designed for physicians, but is also open to physicians-in-training, nurses, students, and mesothelioma patients, families and friends who want to learn more about the disease.

At the 1st and 2nd International Symposia, the distinguished faculty reviewed the results of recent studies and shared their own experiences treating the disease. It was concluded that, especially with advancements in adjuvant therapies, mesothelioma patients should no longer be subjected to lung-amputating EPP surgery which had become commonplace for many physicians.

This year’s symposium will once again bring some of the best scientific and medical minds together to advance the treatment of mesothelioma. According to symposium chair Dr. Robert Cameron: "Research and practice over the past several years have continued to evolve, working to improve cancer outcomes without unnecessarily sacrificing the affected lung. Clearly, it is best for the patient to treat mesothelioma as a chronic illness while preserving the function of both lungs."

The Worthington & Caron Law Firm is proud to once again serve as a sponsor for this unique symposium which focuses on rational lung-sparing surgical and non-surgical therapies for treating pleural mesothelioma. The firm has donated $50,000 for this year’s symposium, matching its contributions of the same amount for the first two years’ symposia. "A one-size fits all approach to mesothelioma simply hasn't worked," said attorney John Caron of Worthington & Caron, who have been representing mesothelioma patients since 1989. "We applaud Dr. Cameron's efforts to assemble the world's brightest doctors to take a fresh look at how to convert this nasty tumor into a chronic, treatable disease."

For a copy of the seminar program, including the schedule, list of speakers and their bios, logistical information and the enrollment application and fees, please click here.

For additional information, please contact Clare Cameron, Executive Director of the Pacific Meso Center at the Pacific Heart, Lung, Blood Institute, at 310-478-4678 or email her at ccameron(at)phlbi(dot)org.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Visit website